Welcome!

News Feed Item

Final Day of the 2014 BIO International Convention to Feature the Annual Scientific American WorldView Scorecard, BIO Idea Hackathon and Look at FDA’s Critical Path Initiative

The 2014 BIO International Convention, the world’s largest biotechnology event, enters its fourth and final day today at the San Diego Convention Center. Hosted by the Biotechnology Industry Organization, this year’s event is expected to attract more than 3,000 biotechnology companies and more than 15,000 attendees from 48 states and 65 countries.

Upcoming Convention Highlights Include:

  • Super Session: Scientific American WorldView Super Session - Biotech: We are the World, Thursday, June 26
    What is happening in biotechnology and life science development on the global stage? What are the most pressing issues of our time that have every nation looking to science as a solution? As the world continues to flatten, individual countries are finding new ways to grow their innovation engines, and in some cases, are hoping to outshine the US. Come to the annual Scientific American WorldView super session to hear a dynamic panel of international industry luminaries examine the future of global innovation in a lively candid conversation. Moderated by television and radio journalist, David Brancaccio, host of Marketplace Morning Report, this session will explore key themes from Scientific American’s annual biotechnology edition, featuring the WorldView Scorecard and fresh perspectives on international life science development.
  • Super Session: The Next Big Deal: The Global Dealmaker Perspective, Thursday, June 26
    2013 delivered in a big way for each of the major deal-making outlets with nearly three times the number of IPOs as in 2012. The M&A market opened up with the total dollars spent on acquisitions reaching the highest in five years. Strong deal terms with large upfront payments for early stage assets were also seen in 2013 as exemplified with Moderna’s $240M upfront from Astrazeneca and Oncomed’s $177M upfront from Celgene. Will these upward trends continue? How will these changing dynamics impact dealmaking in the coming year? What do dealmakers expect will be the result in 2014? Campbell Alliance and BIO are pleased to present updated findings from two unique forward-looking measures of dealmaking in the industry – the Campbell Alliance Dealmakers’ Intentions Study and the BIO One-on-One Partnering Forecast. Based on a survey of more than 150 industry executives, business development professionals, and financial institutions, Dealmakers’ Intentions provides insight into what will likely drive the industry’s partnering and M&A efforts moving forward, and the implications for deal-making over the next year or more. Now in its sixth year, new analysis in 2014 will include year-over-year trends, additional deal metrics, and broader M&A data. Incorporating a global perspective, a highly distinguished panel of dealmakers will then explore the impact these market forces will have on pharmaceutical and biotech companies as they position themselves to make that next big deal.
  • New Technologies to Save Us In a Disaster: Opportunities in the Public-Private Partnership to Develop Medical Countermeasures, Thursday, June 26
    In the decade since the US Congress adopted Project Bioshield, more than $5 billion has been invested in the biodefense sector. This session will explore recent trends and new developments in the advanced development of medical countermeasures (MCMs). The session will provide an update on the status of the Centers of Innovation for Advanced Development and Manufacture and opportunities for drug developers. It will also provide perspectives on the need for novel technologies and key considerations for companies entering the biodefense sector as it matures.
  • The Salford Lung Study: An Innovative 'Real World' Study Design for Chronic Conditions, Thursday, June 26
    The 12-month Salford (UK) Lung Study uses an integrated electronic patient record to assess the safety and effectiveness of Relovair, GlaxoSmithKline's late-phase follow-up to Advair, in chronic obstructive pulmonary disease and asthma. Results are intended to help healthcare decision- makers better assess the drug's potential at an earlier stage. The panel will address the complexities of “real-world” studies and how healthcare providers and regulators can use the data generated to understand the benefits of such studies, particularly for chronic conditions managed in community settings.
  • FDA's Critical Path Initiative: Progress in the First Decade and Promise for the Next, Thursday, June 26
    In 2004, the FDA launched the Critical Path Initiative (CPI), which was a response to the needs and challenges faced by medical product developers. Recognizing that no one organization possesses the resources and expertise to solve medical product development problems, the CPI called for a consortium or public-private-partnership approach to modernize the process whereby FDA-regulated products are developed and evaluated. A brief videotaped overview of the CPI will be provided by its chief architect, Dr. Janet Woodcock (CDER/FDA). Then speakers from the FDA, and industry and non-profit organizations will reflect on certain aspects of CPI that have been accomplished through consortia, present the challenges faced by organizations working in the "pre-competitive" space, and explore options for optimizing future collaborations.
  • Biotech Battle of the Wits 2014, Thursday, June 26
    Back for its third year, well-known biotech journalist Chris Morrison will emcee this rapid-fire, interactive debate on the industry’s hot-button issues featuring three biotech trendsetters. Listen as panelists provide their off-the-cuff opinions on the industry’s most controversial and topical issues. What is the strangest biotech idea you’ve come across? How can a company bounce back from a Phase III failure? To drive the debate, audience members can ask questions live or via Twitter (@BioBanter) and vote for presenters online via Twitter or text. The winner of this session will receive 120 uninterrupted seconds to sound off on the topic of their choice.
  • BIO Career Fair, Thursday, June 26
    The 2014 BIO Career Fair is free to all job seekers. Co-located with the 2014 BIO International Convention, the BIO Career Fair will give attendees access to many of the world’s leading life science companies.

Day Three Session Highlights Included:

Follow the 2014 Convention @BIOConvention, and join the conversation @IAmBIOtech.

The Convention program features more than 160 sessions in 8 breakout sessions and 9 specialty forums. The majority of attendees, 70 percent, are c-level executives. They split evenly from large companies of 500 or more employees and small companies of 50 employees or less.

The BIO International Convention is the largest global event for the biotechnology industry and attracts the biggest names in biotech, offers key networking and partnering opportunities, and provides insights and inspiration on major trends affecting the industry. The Convention will highlight the latest trends and the newest opportunities for executives, investors, scientists, policy leaders, and media from around the world. Speakers at the sessions will share breakthroughs in medicine, diagnostics, the environment, energy production, business operations, financing, partnerships, policy issues and food and agriculture. Visit http://convention.bio.org/program/ for the most up-to-date program and speaker information.

The Convention also features the BIO Business Forum, which has grown over the past thirteen years to become the industry's largest partnering event. This year’s Convention is set to break all previous partnering records, with over 28,000 meetings expected to take place. Powered by BIO's One-on-One Partnering™ System, the BIO Business Forum™ fosters the opportunity for companies to initiate business contacts in a friendly environment and schedule private meetings prior to the Convention.

Upcoming BIO Events

BIO Latin America Conference
September 9-11, 2014
Rio de Janeiro, Brazil

Livestock Biotech Summit
September 16-18, 2014
Sioux Falls, SD

About BIO

BIO is the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. BIOtechNOW is BIO's blog chronicling “innovations transforming our world” and the BIO Newsletter is the organization’s bi-weekly email newsletter. Subscribe to the BIO Newsletter.

For more information:
Visit http://www.bio.org
Follow us on Twitter @IAmBiotech
Join us on LinkedIn/MyBio
Become a fan at facebook.com/IAmBiotech

More Stories By Business Wire

Copyright © 2009 Business Wire. All rights reserved. Republication or redistribution of Business Wire content is expressly prohibited without the prior written consent of Business Wire. Business Wire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Bert Loomis was a visionary. This general session will highlight how Bert Loomis and people like him inspire us to build great things with small inventions. In their general session at 19th Cloud Expo, Harold Hannon, Architect at IBM Bluemix, and Michael O'Neill, Strategic Business Development at Nvidia, discussed the accelerating pace of AI development and how IBM Cloud and NVIDIA are partnering to bring AI capabilities to "every day," on-demand. They also reviewed two "free infrastructure" pr...
With billions of sensors deployed worldwide, the amount of machine-generated data will soon exceed what our networks can handle. But consumers and businesses will expect seamless experiences and real-time responsiveness. What does this mean for IoT devices and the infrastructure that supports them? More of the data will need to be handled at - or closer to - the devices themselves.
Blockchain is a shared, secure record of exchange that establishes trust, accountability and transparency across supply chain networks. Supported by the Linux Foundation's open source, open-standards based Hyperledger Project, Blockchain has the potential to improve regulatory compliance, reduce cost and time for product recall as well as advance trade. Are you curious about Blockchain and how it can provide you with new opportunities for innovation and growth? In her session at 20th Cloud Exp...
DevOps is often described as a combination of technology and culture. Without both, DevOps isn't complete. However, applying the culture to outdated technology is a recipe for disaster; as response times grow and connections between teams are delayed by technology, the culture will die. A Nutanix Enterprise Cloud has many benefits that provide the needed base for a true DevOps paradigm.
Most technology leaders, contemporary and from the hardware era, are reshaping their businesses to do software in the hope of capturing value in IoT. Although IoT is relatively new in the market, it has already gone through many promotional terms such as IoE, IoX, SDX, Edge/Fog, Mist Compute, etc. Ultimately, irrespective of the name, it is about deriving value from independent software assets participating in an ecosystem as one comprehensive solution.
DevOps is often described as a combination of technology and culture. Without both, DevOps isn't complete. However, applying the culture to outdated technology is a recipe for disaster; as response times grow and connections between teams are delayed by technology, the culture will die. A Nutanix Enterprise Cloud has many benefits that provide the needed base for a true DevOps paradigm. In his Day 3 Keynote at 20th Cloud Expo, Chris Brown, a Solutions Marketing Manager at Nutanix, will explore t...
SYS-CON Events announced today that CA Technologies has been named "Platinum Sponsor" of SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, New York, and 21st International Cloud Expo, which will take place in November in Silicon Valley, California.
While some vendors scramble to create and sell you a fancy solution for monitoring your spanking new Amazon Lambdas, hear how you can do it on the cheap using just built-in Java APIs yourself. By exploiting a little-known fact that Lambdas aren’t exactly single threaded, you can effectively identify hot spots in your serverless code. In his session at 20th Cloud Expo, David Martin, Principal Product Owner at CA Technologies, will give a live demonstration and code walkthrough, showing how to o...
New competitors, disruptive technologies, and growing expectations are pushing every business to both adopt and deliver new digital services. This ‘Digital Transformation’ demands rapid delivery and continuous iteration of new competitive services via multiple channels, which in turn demands new service delivery techniques – including DevOps. In this power panel at @DevOpsSummit 20th Cloud Expo, moderated by DevOps Conference Co-Chair Andi Mann, panelists will examine how DevOps helps to meet th...
SYS-CON Events announced today that Hitachi, the leading provider the Internet of Things and Digital Transformation, will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Hitachi Data Systems, a wholly owned subsidiary of Hitachi, Ltd., offers an integrated portfolio of services and solutions that enable digital transformation through enhanced data management, governance, mobility and analytics. We help globa...
DevOps is being widely accepted (if not fully adopted) as essential in enterprise IT. But as Enterprise DevOps gains maturity, expands scope, and increases velocity, the need for data-driven decisions across teams becomes more acute. DevOps teams in any modern business must wrangle the ‘digital exhaust’ from the delivery toolchain, "pervasive" and "cognitive" computing, APIs and services, mobile devices and applications, the Internet of Things, and now even blockchain.
@DevOpsSummit has been named the ‘Top DevOps Influencer' by iTrend. iTred processes millions of conversations, tweets, interactions, news articles, press releases, blog posts - and extract meaning form them and analyzes mobile and desktop software platforms used to communicate, various metadata (such as geo location), and automation tools. In overall placement, @DevOpsSummit ranked as the number one ‘DevOps Influencer' followed by @CloudExpo at third, and @MicroservicesE at 24th.
SYS-CON Events announced today that T-Mobile will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. As America's Un-carrier, T-Mobile US, Inc., is redefining the way consumers and businesses buy wireless services through leading product and service innovation. The Company's advanced nationwide 4G LTE network delivers outstanding wireless experiences to 67.4 million customers who are unwilling to compromise on ...
The goal of Continuous Testing is to shift testing left to find defects earlier and release software faster. This can be achieved by integrating a set of open source functional and performance testing tools in the early stages of your software delivery lifecycle. There is one process that binds all application delivery stages together into one well-orchestrated machine: Continuous Testing. Continuous Testing is the conveyor belt between the Software Factory and production stages. Artifacts are ...
SYS-CON Events announced today that Juniper Networks (NYSE: JNPR), an industry leader in automated, scalable and secure networks, will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Juniper Networks challenges the status quo with products, solutions and services that transform the economics of networking. The company co-innovates with customers and partners to deliver automated, scalable and secure network...